アブストラクト
| Title | irAEの対策・対応 |
|---|---|
| Subtitle | 特集2 免疫チェックポイント阻害薬の使い方 & irAE対策 免疫関連有害事象 (irAE) 対策 |
| Authors | 横田知哉 |
| Authors (kana) | |
| Organization | 静岡県立静岡がんセンター消化器内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 6 |
| Page | 1140-1144 |
| Year/Month | 2023 / 5 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●免疫関連有害事象(irAE)は多彩な臨床症状を呈し, ときに生命を脅かす重篤な場合もある. ●irAEの対策として, 早期発見と早期治療介入が重要であり, 多職種で連携しつつ, 重症度に応じた管理が必要である. ●irAEを症候ベースで考えるのではなく, 原因となる臓器の病因ベースで考えることによって, 速やかに適切な治療が開始できる. ●irAEに対する治療の原則は, 重症度に応じて適切な免疫抑制薬の投与を行うことである. ●ICIを含む併用療法中に有害事象が生じた際は, できる限り原因薬剤を追及することが必要である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Khoja L, et al : Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors : a systematic review. Ann Oncol, 28 : 2377-2385, 2017
- 2) Chana Weinstock, et al : FDA analysis of patients with baseline autoimmune diseases treated with PD-1 / PD-L1 immunotherapy agents. J Clin Oncol, 35, 2017
- 3) Leonardi GC, et al : Safety of programmed death-1 pathway inhibitors among patients with non-dmall-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol, 36 : 1905-1912, 2018
- 4) Brahmer JR, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 36 : 1714-1768, 2018
- 5) Haanen JBAG, et al : Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28 : iv119-iv142, 2017
残りの8件を表示する
- 6) 日本臨床腫瘍学会・編 : がん免疫療法ガイドライン 第2版. 金原出版, 2019
- 7) Puzanov I, et al : Managing toxicities associated with immune checkpoint inhibitors : consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group. J Immunother Cancer, 5 : 95, 2017
- 8) Teulings HE, et al : Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival : A systematic review and meta-analysis. J Clin Oncol, 33 : 773-781, 2015
- 9) Maher VE, et al : Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol, 37 : 2730-2737, 2019
- 10) Foster CC, et al : Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer, 127 : 4565-4573, 2021
- 11) Simonaggio A, et al : Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol, 5 : 1310-1317, 2019
- 12) Abu-Sbeih H, et al : Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol, 37 : 2738-2745, 2019
- 13) Nakajima EC, et al : Challenge of rechallenge : When to resume immunotherapy following an immune-related adverse event. J Clin Oncol, 37 : 2714-2718, 2019
